8-K: XWELL Reports 2025 Results, Expands Wellness & Biosecurity

XWELL, Inc. announced fiscal year 2025 financial results, reporting $29.2 million in revenue, reduced operating expenses, and strategic expansions in wellness and biosecurity.

Summary

• Fiscal year 2025 revenue was approximately $29.2 million, with XpresSpa contributing $18.6 million, XpresCheck $8.3 million, and Naples Wax Center $2.3 million.
• Total operating expenses decreased by approximately 10% to $23.2 million compared to $25.6 million in the prior year.
• Cost of sales decreased by approximately 13% to $21.7 million from $25.0 million in 2024.
• General and administrative expenses saw a year-over-year decrease of approximately 20%.
• Operating loss improved to approximately $15.7 million from $16.7 million in the comparable prior year period.
• Net loss attributable to XWELL slightly increased to approximately $17.0 million from $16.9 million in the prior year.
• As of December 31, 2025, the company had approximately $2.6 million in cash and cash equivalents (excluding restricted cash) and no long-term debt.
• Subsequent to year-end, XWELL completed a private placement in February 2026, raising approximately $31.3 million in gross proceeds.
• Strategic expansions include new wellness retail locations in New York City's Penn Station (December 2025) and two Florida locations (Q3 2025).
• The company secured a three-year extension for its Traveler-based Genomic Surveillance Program (TGS) with the CDC and Ginkgo Bioworks in March 2025.
• A strategic partnership with PieQ was formed in February 2026 to develop a novel U.S. biosecurity forecasting platform.
• Dr. Cindy Friedman, former CDC senior advisor, was appointed as a senior advisor for global biosecurity initiatives in February 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to significant cost reductions, strategic expansion into new markets, and a substantial capital raise that strengthens the balance sheet and supports future growth initiatives, despite a slight increase in net loss.

Positives

• Total operating expenses decreased by approximately 10% year-over-year.
• Cost of sales decreased by approximately 13% year-over-year.
• General and administrative expenses decreased by approximately 20% year-over-year.
• Operating loss improved to $15.7 million from $16.7 million in the prior year.
• Successful expansion of wellness channels with new off-airport locations in New York City's Penn Station and two Florida markets.
• Secured a three-year extension for the Traveler-based Genomic Surveillance Program (TGS) with the CDC and Ginkgo Bioworks.
• Formed a strategic partnership with PieQ to develop a novel U.S. biosecurity forecasting platform.
• Appointment of Dr. Cindy Friedman, former CDC senior advisor, as a senior advisor for global biosecurity.
• Strong liquidity position post-private placement, with approximately $31.3 million in gross proceeds and no long-term debt as of December 31, 2025.

Negatives

• Net loss attributable to XWELL slightly increased to approximately $17.0 million in 2025 from $16.9 million in 2024.
• The company continues to report an operating loss of $15.7 million.

Risks

• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• Important factors that could cause actual results or events to differ materially are discussed in the company's filings with the SEC, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, proxy statements, registration statements, and other documents.

Future Outlook

XWELL believes it is well positioned to create long-term value by continuing to execute against strategic priorities, expanding outside of airports, diversifying access points, and elevating brand relevance. The company plans to leverage its traveler-based pathogen surveillance capabilities to support international travel hubs and large-scale mass gathering events worldwide.

Management Comments

• "We continue to execute against our strategic priorities by expanding outside of the airport, diversifying access points and elevating brand relevance."
• "The opening of our off-airport wellness center in Penn Station and growth across key Florida markets reflects XWELLs ability to extend services beyond the airport and into the everyday lives of our customers."
• "Coupled with our long-standing CDC partnership and ongoing operational discipline, we believe XWELL is well positioned to create long-term value."

Industry Context

StockSavvy.ai notes that XWELL's expansion into off-airport wellness centers and its continued focus on biosecurity align with broader trends in the health and wellness industry, particularly the increasing demand for accessible wellness services and enhanced public health infrastructure. The strategic partnership with PieQ and the appointment of Dr. Friedman underscore a commitment to leveraging technology and expertise in the growing global biosecurity market, potentially positioning XWELL as a key player in pathogen surveillance beyond traditional travel settings.

Comparison to Industry Standards

• The reported 10% decrease in total operating expenses and 13% decrease in cost of sales suggest effective cost management, which is a positive indicator in the competitive wellness and travel services sector. This efficiency could compare favorably to peers struggling with post-pandemic operational costs.
• The expansion into off-airport locations like Penn Station and Florida retail centers demonstrates a strategy similar to other wellness brands diversifying their physical footprint to capture broader consumer segments, moving beyond niche markets.
• The biosecurity initiatives, particularly the CDC partnership and international expansion, position XWELL in a unique niche. While direct comparisons are difficult, the long-term contract extensions and strategic hires like Dr. Friedman suggest a robust commitment to a growing public health sector, potentially outperforming smaller, less specialized biosecurity firms.
• The private placement of $31.3 million significantly bolsters liquidity, providing a stronger financial foundation compared to many smaller companies in the wellness space that might face capital constraints.

Management Changes

Stakeholder Impact

• Shareholders: The private placement and improved liquidity could be seen positively, reducing financial risk and funding growth. The slight increase in net loss might be a concern, but operational improvements and strategic growth initiatives could offset this.
• Customers: Expansion into new off-airport locations and diversified wellness offerings provide more accessible services. The biosecurity programs enhance public health safety for travelers.
• Employees: Continued growth and strategic initiatives may lead to job stability and potential expansion opportunities.
• Creditors: Repurchasing outstanding notes and redeeming preferred stock/warrants using private placement proceeds strengthens the balance sheet and reduces certain liabilities.

Next Steps

• Use proceeds from the private placement to repurchase certain outstanding notes, redeem Series G Preferred Stock and certain warrants.
• Utilize remaining private placement proceeds for general corporate purposes and working capital needs.
• Continue to execute against strategic priorities by expanding outside of the airport, diversifying access points, and elevating brand relevance.
• Leverage traveler-based pathogen surveillance capabilities to support international travel hubs and large-scale mass gathering events worldwide.
• Dr. Cindy Friedman is expected to provide strategic guidance on the design and adaptation of traveler-based surveillance approaches for select international biosecurity initiatives.

Key Dates

Recommendation

While XWELL demonstrated strong operational improvements with significant cost reductions and strategic expansions into new wellness and biosecurity markets, the slight increase in net loss and continued overall loss position suggest that the company is still in a growth and investment phase. The substantial capital raise provides a strong financial buffer and supports future initiatives, but investors should await further evidence of sustained profitability or a clear path to it before considering a 'buy' recommendation. The strategic moves are positive, but the financial results are not yet compelling enough for a strong buy, nor are they poor enough for a sell, making 'hold' appropriate for existing investors to monitor progress.

Keywords

XWELL, XWEL, Financial Results, 2025, Wellness Solutions, Biosecurity, XpresSpa, XpresCheck, Naples Wax Center, CDC Partnership, Private Placement, Operating Expenses, Revenue, Net Loss, Nasdaq